Measurement of Gal-3 was recommended by the 2013 American College of Cardiology Foundation/American Heart Association (ACCF/AHA) clinical Guidelines as class IIb for management and risk prediction in heart failure (HF) [9]. This evidence concerns the gene LGALS3 and hydrops fetalis.